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ABSTRACT: The YcaO superfamily of proteins catalyz-
es the phosphorylation of peptide backbone amide 
bonds, which leads to the formation of azolines and az-
oles in ribosomally synthesized and post-translationally 
modified peptides (RiPPs). Bottromycins are RiPPs with 
potent antimicrobial activity, and their biosynthetic 
pathway contains two divergent, stand-alone YcaO en-
zymes, IpoC and PurCD. From an untargeted metabo-
lomics approach, it had been suggested that PurCD acts 
with a partner protein to form the 12-membered 
macroamidine unique to bottromycins. Here we report 
the biochemical characterization of IpoC and PurCD. 
We demonstrate that IpoC installs a cysteine-derived 
thiazoline, while PurCD alone is sufficient to create the 
macroamidine structure. Both enzymes are catalytically 
promiscuous and we generated 10 different macroami-
dines. Our data provide important insights into the ver-
satility of YcaO enzymes, their ability to utilize different 
nucleophiles and provide a framework for the creation of 
novel bottromycin derivatives with enhanced bioactivity. 
Bottromycins (Scheme 1) are ribosomally synthesized 
and post-translationally modified peptide (RiPP) natural 
products that bind to the A site of the 50S ribosome, thus 
inhibiting prokaryotic protein synthesis and represent a 
novel class of antibiotics.1 They are derived from the 
precursor peptide BotA, which is unique amongst the 
RiPPs family in that it has a C-terminal “follower” ra-
ther than the canonical N-terminal “leader” peptide.2-5 
BotA is tailored by a series of enzymatic (and possibly 
non-enzymatic) chemical transformations and their order 
has recently been proposed based on data from an untar-
geted metabolomics approach (Scheme 1).6 The bottro-
mycin biosynthetic gene cluster contains two unusual, 
stand-alone YcaO-domain enzymes, BotC and BotCD 
(sequence identity of 26%, Figure S2). 
YcaO-domain proteins were enigmatic until they were 
linked to the formation of azol(in)e heterocycles in the 
biosynthesis of microcin B17.7-8 Biosynthetic pathways 
responsible for the production of RiPPs frequently con-
tain enzymes with a YcaO domain, which catalyze az-
oline formation in an ATP-dependent cyclodehydration 
reaction.9 
Scheme 1. a) Bottromycin biosynthesis with the pro-
posed functions of the two YcaO enzymes. b) Use of a 
terminal amine by a YcaO enzyme as a nucleophile to 
achieve macroamidine formation. 
 
Vital for this process in all RiPPs systems studied to date 
is the presence of RiPP recognition element (RRE) do-
mains.10 Without the RRE domain of a specific system, 
which can either be present on a stand-alone E1 ubiqui-
tin activating-like superfamily protein or part of a multi-
domain heterocyclase, the heterocyclase activity is min-
imal.11 The YcaO domain of the responsible enzyme 
catalyzes the nucleophilic attack of a Cys/Ser/Thr side-
chain on the preceding backbone carbonyl to form a 
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hemiorthoamide.12 This intermediate is then O-
phosphorylated12 (or pyrophosphorylated13) followed by 
an elimination reaction to yield the azoline (Figure S1a). 
It has been proposed (and one example reported14) that 
other nucleophiles may also be used by this enzyme 
family. Despite the presence of two YcaO enzymes, bot-
tromycins contain only one azole and the gene cluster 
encodes no E1-like protein or known RRE domain. An 
untargeted metabolomic approach using mass spectral 
networking identified the order of reactions in bottromy-
cin biosynthesis.6 This study revealed that BotC was 
responsible for the formation of the thiazoline, while 
BotCD (in cooperation with a hydrolase) catalyzed the 
macrocyclization reaction to yield the macroamidine.6 
Macroamidine formation can be viewed as analogous to 
azoline formation, with the amino-terminus of the pre-
cursor peptide BotA functioning as the nucleophile 
(Scheme 1b and Figure S1b). 
 
Figure 1. MS2 characterization of BotAP after incubation 
with IpoC and BotAPC after incubation with PurCD. Full 
details of the MS2 fragmentation are provided in Figures 
S4-S6 and Tables S1-S5. Signals in the BotAPCCD spectra 
that likely come from residual BotAPC are labelled with 
triangles. 
To investigate this potentially novel YcaO-domain catal-
ysis, we sought to characterize BotC and BotCD in vitro, 
but neither protein (from Streptomyces sp BC16019) 
could be expressed in a soluble form. In contrast, the 
homologs IpoC (76% sequence identity to BotC) from 
Streptomyces ipomoeae and PurCD (81% sequence iden-
tity to BotCD) from Streptomyces purpureus were trac-
table. Both proteins originate from gene clusters that are 
homologous and highly similar to those reported to pro-
duce bottromycins (Figure S3). When BotA was incu-
bated with IpoC and ATP/Mg2+, we observed a loss of 
18 Da (Figure S4a), and the conversion of Cys9 to thia-
zoline was confirmed by tandem MS (MS2) (Figure S4b 
and Table S2). We treated BotA with BotP (BotAP) to 
make the glycine amino group available as a nucleophile 
for macrocyclization and repeated the experiments.15 
The reaction with IpoC also resulted in thiazoline for-
mation at Cys9 (Figure 1 and S5, Table S4). For PurCD 
incubated with BotAP we also observed a loss of 18 Da, 
but the yield was too low for MS2 analysis (Figure S5a). 
Based on metabolomic data, we expected the heterocy-
clized intermediate (BotAPC) to be a better PurCD sub-
strate.6 When we reacted purified BotAPC with PurCD 
and ATP/Mg2+ we observed macroamidine formation 
(BotAPCCD), which was confirmed by MS2, where char-
acteristic6 macroamidine fragments of m/z 335.21, 
363.20 and 434.28 were observed (Figures 1 and S6, 
Table S5). Neither BotA nor heterocyclized BotAC were 
substrates for PurCD. These data established IpoC as the 
heterocyclase, while PurCD functions as the macrocy-
clase. PurCD is the first reported case of a YcaO enzyme 
able to a) utilize nitrogen as a nucleophile and b) form 
larger ring systems. Our data indicates that for efficient 
catalysis removal of the N-terminal methionine precedes 
heterocyclization, which is followed by macrocylization. 
A detailed analysis of the IpoC-catalyzed heterocycliza-
tion showed that 50 µM BotAP required 8 h to reach 
completion when it was incubated with 5 µM IpoC and 
5 mM ATP/Mg2+ at 37 °C (Figure 2a). In contrast, the 
reaction using unprocessed precursor peptide BotA re-
quired 16 h (Figure 2a). The heterocyclization rate was 
calculated to be 0.1 heterocycles per enzyme per minute 
with BotAP, while the reaction using BotA was roughly 
half this rate (Figure S7), indicating that while IpoC can 
process both versions of the precursor peptide, BotAP is 
preferred. Changes in the reaction conditions (tempera-
ture, pH, salt concentration) did not lead to accelerated 
heterocycle formation (data not shown). 
 
Figure 2. a) Time-course of IpoC-catalyzed heterocycliza-
tion of BotA (red) and BotAP (black) at pH 7.4. b) Time-
course of PurCD-catalyzed macroamidine formation at pH 
9.5. c) Effects of BotAP truncations and follower peptide on 
IpoC and PurCD stability (pH 8.5) and turnover (pH 7.4 
and 9.5, respectively). 
The macrocyclization reaction of PurCD (10 µM) with 
BotAPC (50 µM) was approximately 15 % complete after 
90 min at pH 7.5 (Figure S8a). We hypothesized that the 
reaction may be accelerated by increasing the pH of the 
reaction as increasing the pH results in a larger propor-
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tion of deprotonated substrate N-terminus, which is then 
available as the nucleophile for macroamidine for-
mation. We analyzed PurCD activity between pH 7 and 
11, which is more than 1 pH unit above the pKa of the 
amino group of glycine (pKa 9.6), so most of the sub-
strate should be available in its neutral (nucleophilic) 
form. We observed a steady increase in product for-
mation with a maximum at pH 9.5 (Figure S8b), with 
~85% turnover after 1 h (Figures 2b and S8c). We won-
dered if the decrease in enzyme activity above pH 9.5 
was due to enzyme degradation. When we analyzed 
PurCD stability by measuring its melting temperature 
(Tm) in thermal shift assays (TSAs), we observed a 
steady decrease of enzyme stability with increasing pH 
and were unable to record a Tm at pH 11 (Figure S9a). 
We therefore believe that pH 9.5 represents the best bal-
ance between substrate availability and enzyme stability. 
Interestingly, we the enzyme and ATP-dependent reo-
pening of the macroamidine after extended incubations 
of the reactions, which was accelerated at lower pH 
(Figure S8). After 12 h no BotAPCCD could be observed 
in the samples. It appears possible, that the hydrolase 
identified as essential for macroamidine formation in 
vivo6 influences this reaction’s equilibrium and thus pre-
vents re-opening of the ring. IpoC and PurCD appear to 
be tractable for the use in in vitro systems, but the sur-
prising enzyme-induced hydrolysis of the macroamidine 
by PurCD must be taken into account in such systems to 
accomplish satisfactory yields. 
A hallmark of YcaO domains characterized to date is 
their requirement to bind their substrate’s leader peptide 
for efficient catalysis via an RRE domain. The bottro-
mycin gene cluster does not encode a protein with ho-
mology to known RREs, and we investigated if IpoC 
and PurCD were able to bind the follower peptide of 
BotA. Based on published precursor peptide – enzyme 
structures, binding to the leader appears to stabilize the 
corresponding enzyme.13,16 This feature would allow 
TSAs to be used as a convenient tool to probe these crit-
ical interactions. In TSAs, one can measure the Tm of a 
protein in the absence and presence of ligands and stabi-
lizing interactions between protein and ligand lead to an 
increase in Tm. IpoC and PurCD had Tms of 33 and 24 
°C, respectively, which increased dramatically after the 
addition of the substrate BotAP/BotAPC (Figure S9b and 
Table S6). To verify that this effect was not exerted by 
the core peptide, we repeated the experiment using fol-
lower peptide BotA-F. The effect of the follower on Ip-
oC was almost as pronounced as for BotAP (Figure 
S10a). In the case of PurCD, the differences between 
BotAPC and BotA-F were within the experimental error 
(Figures 2c and S10b, Table S6). We asked if the pres-
ence of the substrate cysteine had an effect on IpoC sta-
bility and observed a drastic increase in Tm for IpoC + 
BotA-F with an additional N-terminal cysteine (Figures 
2c and S10a, Table S6). To identify the follower region 
responsible for binding we produced a series of system-
atic truncations (Figures 2c and S10, Tables S7 and S8). 
BotAP with the 5 C-terminal residues removed (BotAP-
5AA) had a slightly less stabilizing effect on IpoC and 
PurCD when compared to BotAP and was processed 
with similar efficiency. Removal of the next 5 residues 
(BotAP-10AA) abolished the stabilizing effect on both 
enzymes, severely hampered processing by IpoC and 
abolished PurCD activity. The next truncation, BotAP-
15AA, had no stabilizing effect on either enzyme and 
was not processed. These data indicated that the region 
between residues 30 and 39 is critical for the interaction 
between BotA and both enzymes. We produced a series 
of point mutants covering this area (Figure S11, Tables 
S7 and S8), which all showed a reduced stabilizing ef-
fect in TSAs, with E31R and W35A reducing the effect 
to within experimental error. However, all point mutants 
could be processed by both enzymes (Figure S12). Only 
BotAPE28R, a mutation slightly outside the suggested 
range, abolished stabilization and processing, highlight-
ing the importance of this residue. The observation that 
impairment of substrate binding (implied via Tms) does 
not abolish processing has been observed for other YcaO 
enzymes. A deeper understanding will require the deter-
mination of C and CD crystal structures in complex with 
BotA-F. However, we have demonstrated that the stabi-
lizing effect of the follower or leader peptides observed 
in TSAs may be used to group tailoring enzymes into 
early (requiring leader/follower) and late (acting after 
leader/follower removal) enzymes, to reduce the com-
plexity of reconstituting RiPPs pathways in vitro. 
 
Figure 3. a) Tolerance of IpoC and PurCD to changes in the 
core peptide of BotA. Conversion rate given in relation to 
wt substrate. Effect of b) IpoC and c) PurCD ATP/Mg2+ 
binding residue mutations on enzyme activity. 
The YcaO enzymes studied to date have shown a great 
tolerance for changes in their respective substrates9 and 
we wondered if IpoC and PurCD would also display 
catalytic promiscuity. To this end we tested a set of 18 
core peptide mutants (Figure S13, Tables S7 and S8). 
IpoC was unable to produce oxazoline from a C9S mu-
tant, but processed 13 other point mutants (Figures 3a 
and S14). The most sensitive position appeared to be V5. 
The 13 heterocyclized peptides were tested for reactivity 
with PurCD. We observed macroamidine formation for 
10 of these (Figures 3a and S15, Table S8) with varying 
conversion rates. Our data indicates that Gly2 cannot be 
 4 
modified, and the requirement of a glycine at this posi-
tion was likely, since aside from D-amino acids17 it in-
troduces the least strain into the ring system and is the 
nucleophile in macrocyclization. 
To date, only two YcaO domain proteins have been crys-
tallized in complex with a nucleotide cofactor. Both are 
very distantly related to IpoC and PurCD (pairwise pro-
tein sequence identity < 20%), but sequence alignment 
nevertheless revealed that key ATP and Mg2+ binding 
residues are mostly conserved (Figure S16). To explore 
IpoC and PurCD ATP binding residues, we designed a 
series of point mutants of both enzymes based on the 
sequence alignments (Figure S16, Tables S7 and S8). In 
IpoC we mutated the putative Mg2+ binding residue E59 
to A or R, while we swapped the putative ATP (phos-
phate) binding residue R234 to A or E. All four mutants 
could be expressed, purified and stabilized by BotAP 
(TSAs), indicating correct protein folding (Figure S17 
and Table S6). The stabilizing effect of ATP/Mg2+ re-
mained as observed for wild-type IpoC, within experi-
mental error. Mutations of E59 reduced activity to less 
than 5% of wt enzyme, while mutations of R234 reduced 
enzymatic activity (Figure 3b and S18). Equivalent in 
vivo mutants (Table S9) were consistent with this in vitro 
data. In PurCD we selected E94 (to A or R) and R310 (to 
A or E) for mutations. Here, only the conservative ala-
nine substitutions could be expressed. Both mutant pro-
teins were stabilized by BotAP and ATP/Mg2+ as ob-
served for wt PurCD, but were unable to process sub-
strate (Figures 3c, S19 and S20, Tables S7 and S8). 
These deleterious in vitro results for PurCD were con-
firmed when the same mutations were tested in vivo 
(Table S9), which all provided the same metabolite pro-
file as a gene deletion. The conservation of key 
ATP/Mg2+ binding residues in highly divergent enzymes 
from this family may be used to validate predicted YcaO 
domain enzymes in vitro or in vivo and offers a way to 
selectively abolish enzyme function without disrupting 
protein folding. 
We have demonstrated that the catalytic repertoire of 
YcaO enzymes also includes the formation of macroam-
idines. This enzyme family has also been implied in the 
formation of thioamide bonds,18 and it will be fascinat-
ing to discover their true chemical scope. The promis-
cuity of these two key biosynthetic enzymes in vitro is 
an important cornerstone towards the development of an 
efficient system to generate bottromycin variants with 
enhanced stability and activity. 
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